risedronic acid has been researched along with Crohn Disease in 5 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Crohn Disease: A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with Crohn's disease have an increased frequency of osteopenia and osteoporosis." | 2.77 | Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial. ( Fedorak, RN; McQueen, B; Siffledeen, J; Siminoski, K; Soo, I, 2012) |
| " A random-effects model within a Bayesian framework was applied to compare treatment effects as standardized mean difference (SMD) with their corresponding 95% credible interval (CrI), while odds ratio (OR) was applied to compare adverse events with 95% CrI." | 2.55 | Efficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease: A systematic review with network meta-analysis. ( Chen, H; Ma, H; Ma, J; Wang, P; Zhang, H; Zhang, Y; Zhao, X; Zhou, C; Zhu, Y, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van Bodegraven, AA | 1 |
| Bravenboer, N | 1 |
| Witte, BI | 1 |
| Dijkstra, G | 1 |
| van der Woude, CJ | 1 |
| Stokkers, PC | 1 |
| Russel, MG | 1 |
| Oldenburg, B | 1 |
| Pierik, M | 1 |
| Roos, JC | 1 |
| van Hogezand, RA | 1 |
| Dik, VK | 1 |
| Oostlander, AE | 1 |
| Netelenbos, JC | 1 |
| van de Langerijt, L | 1 |
| Hommes, DW | 1 |
| Lips, P | 1 |
| Bernstein, CN | 1 |
| Targownik, LE | 1 |
| Leslie, WD | 1 |
| Zhao, X | 1 |
| Zhou, C | 1 |
| Chen, H | 1 |
| Ma, J | 1 |
| Zhu, Y | 1 |
| Wang, P | 1 |
| Zhang, Y | 1 |
| Ma, H | 1 |
| Zhang, H | 1 |
| Soo, I | 1 |
| Siffledeen, J | 1 |
| Siminoski, K | 1 |
| McQueen, B | 1 |
| Fedorak, RN | 1 |
| Namazi, H | 1 |
1 review available for risedronic acid and Crohn Disease
| Article | Year |
|---|---|
Efficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease: A systematic review with network meta-analysis.
Topics: Alendronate; Bayes Theorem; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic | 2017 |
2 trials available for risedronic acid and Crohn Disease
| Article | Year |
|---|---|
Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabo | 2014 |
Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabo | 2012 |
2 other studies available for risedronic acid and Crohn Disease
| Article | Year |
|---|---|
What is the role for bisphosphonates in IBD?
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Crohn Disease; Dietary Suppleme | 2014 |
Risedronate improves bone mineral density in Crohn's disease: a complementary mechanism.
Topics: Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Crohn Disease; Etidronic A | 2012 |